Sarcopenia in solid organ transplantation

Nutrition in Clinical Practice

Volumn 29, Issue 2, 2014, Pages 159-170

  Carey, Elizabeth J ^a  

^a MAYO CLINIC   (United States)

Author keywords

malnutrition; nutrition; nutrition assessment; organ transplantation; sarcopenia

Indexed keywords

ANABOLIC AGENT; BETA HYDROXY BETA METHYLBUTYRATE; CREATININE; DRUG METABOLITE; GHRELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSTATIN; PROTEASOME; RECOMBINANT GROWTH HORMONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; TRANSCRIPTION FACTOR FOXO; UBIQUITIN; UNCLASSIFIED DRUG;

ABDOMINAL WALL MUSCULATURE; AEROBIC CAPACITY; AGING; ANTHROPOMETRY; BODY COMPOSITION; CACHEXIA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROSTIMULATION THERAPY; END STAGE RENAL DISEASE; FUNCTIONAL STATUS; HEART TRANSPLANTATION; HISTORY; HUMAN; IMPEDANCE; INSULIN RESISTANCE; KINESIOTHERAPY; LEAN BODY WEIGHT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEDICAL LITERATURE; MODEL FOR END STAGE LIVER DISEASE SCORE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PREVALENCE; PROTEIN DEGRADATION; PSOAS MUSCLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; REVIEW; SARCOPENIA; SKELETAL MUSCLE; TREATMENT OUTCOME; WALKING;

MALNUTRITION; NUTRITION; NUTRITION ASSESSMENT; ORGAN TRANSPLANTATION; SARCOPENIA;

HUMANS; MUSCLE, SKELETAL; ORGAN TRANSPLANTATION; SARCOPENIA;

EID: 84896382879     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533613520619     Document Type: Review

References (115)

1. Rosenberg IH. Summary comments. Am J Clin Nutr. 1989 ; 50: 1231-1233
2. Evans WJ. What is sarcopenia?. J Gerontol A Biol Sci Med Sci. 1995 ; 50: 5-8
3. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997 ; 127 (5). 990S - 991S
4. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993 ; 123 (2). 465-468
5. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011 ; 12 (4). 249-256
6. Morley JE, Abbatecola AM, Argiles JM, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011 ; 12 (6). 403-409
7. Desmeules S, Levesque R, Jaussent I, Leray-Moragues H, Chalabi L, Canaud B. Creatinine index and lean body mass are excellent predictors of long-term survival in haemodiafiltration patients. Nephrol Dial Transplant. 2004 ; 19 (5). 1182-1189
8. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008 ; 9 (7). 629-635
9. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013 ; 108 (5). 1034-1041
10. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012 ; 107 (6). 931-936
11. Hook JL, Lederer DJ. Selecting lung transplant candidates: where do current guidelines fall short?. Exp Rev Respir Med. 2012 ; 6 (1). 51-61
12. Englesbe MJ. Quantifying the eyeball test: sarcopenia, analytic morphomics, and liver transplantation. Liver Transpl. 2012 ; 18 (10). 1136-1137
13. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 ; 147 (8). 755-763
14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 ; 39 (4). 412-423
15. Am J Respir Crit Care Med. 2002 ; 166 (1). 111-117
16. Carey EJ, Steidley DE, Aqel BA, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010 ; 16 (12). 1373-1378
17. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008 ; 73 (4). 391-398
18. Fearon K, Evans WJ, Anker SD. Myopenia - a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle. 2011 ; 2 (1). 1-3
19. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 ; 56: M146 - M156
20. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998 ; 85 (1). 115-122
21. Abellan van Kan G, Houles M, Vellas B. Identifying sarcopenia. Curr Opin Clin Nutr Metab Care. 2012 ; 15 (5). 436-441
22. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000 ; 89 (2). 465-471
23. Patel SS, Molnar MZ, Tayek JA, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013 ; 4 (1). 19-29
24. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012 ; 10 (2). 166 173.e1-173
25. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value. Liver Transpl. 2012 ; 18 (10). 1209-1216
26. Carrero JJ, Chmielewski M, Axelsson J, et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr. 2008 ; 27 (4). 557-564
27. Kim JK, Choi SR, Choi MJ, et al. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr. :
28. Johansen KL, Shubert T, Doyle J, Soher B, Sakkas GK, Kent-Braun JA. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int. 2003 ; 63 (1). 291-297
29. Honda H, Qureshi AR, Axelsson J, et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr. 2007 ; 86 (3). 633-638
30. McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant. 2006 ; 21 (8). 2210-2216
31. Fulster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013 ; 34 (7). 512-519
32. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993 ; 147 (5). 1151-1156
33. Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J. 1994 ; 7 (10). 1793-1797
34. Reppert S, Jensen M, Eiken C, Kennedy C. Use of software imaging to detect sarcopenia in lung transplant candidates. Am J Transplant. 2013 ; 5 (3). 301
35. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010 ; 211 (2). 271-278
36. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl. 2013 ; 19 (12). 1396-1402
37. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013 ; 25 (1). 85-93
38. Schutz T, Hudjetz H, Roske AE, et al. Weight gain in long-term survivors of kidney or liver transplantation - another paradigm of sarcopenic obesity?. Nutrition. 2012 ; 28 (4). 378-383
39. Domanski M, Ciechanowski K. Sarcopenia: a major challenge in elderly patients with end-stage renal disease. J Aging Res. 2012 ; 2012: 754739
40. Noori N, Kopple JD, Kovesdy CP, et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2010 ; 5 (12). 2258-2268
41. Kaysen GA. Diabetes, a cause of progressive sarcopenia in dialysis patients?. Kidney Int. 2005 ; 68 (5). 2396-2397
42. Streja E, Molnar MZ, Kovesdy CP, et al. Associations of pretransplant weight and muscle mass with mortality in renal transplant recipients. Clin J Am Soc Nephrol. 2011 ; 6 (6). 1463-1473
43. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997 ; 349 (9058). 1050-1053
44. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005 ; 82 (1). 53-59
45. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006 ; 173 (1). 79-83
46. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 ; 166 (6). 809-813
47. Cesari M, Pedone C, Chiurco D, et al. Physical performance, sarcopenia and respiratory function in older patients with chronic obstructive pulmonary disease. Age Ageing. 2012 ; 41 (2). 237-241
48. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997 ; 30 (7). 1758-1764
49. Garonzik-Wang JM, Govindan P, Grinnan JW, et al. Frailty and delayed graft function in kidney transplant recipients. Arch Surg. 2012 ; 147 (2). 190-193
50. Jones JC, Coombes JS, Macdonald GA. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl. 2012 ; 18 (2). 146-151
51. Singer J, Yelin EH, Katz PP, et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev. 2011 ; 31 (2). 111-119
52. Martinu T, Babyak MA, O'Connell CF, et al. Baseline 6-min walk distance predicts survival in lung transplant candidates. Am J Transplant. 2008 ; 8 (7). 1498-1505
53. Tuppin MP, Paratz JD, Chang AT, et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant. 2008 ; 27 (7). 729-734
54. Kohl Lde M, Signori LU, Ribeiro RA, et al. Prognostic value of the six-minute walk test in end-stage renal disease life expectancy: a prospective cohort study. Clinics (Sao Paulo). 2012 ; 67 (6). 581-586
55. Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000 ; 94 (9). 859-867
56. Cicoira M, Davos CH, Francis DP, et al. Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. J Card Fail. 2004 ; 10 (5). 421-426
57. Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci. 2013 ; 68 (8). 968-975
58. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999 ; 33 (4). 959-965
59. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J. 1997 ; 10 (12). 2807-2813
60. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle. 2012 ; 3 (3). 163-179
61. Coats AJ. Research on cachexia, sarcopenia and skeletal muscle in cardiology. J Cachexia Sarcopenia Muscle. 2012 ; 3 (4). 219-223
62. Wang XH, Mitch WE. Muscle wasting from kidney failure - a model for catabolic conditions. Int J Biochem Cell Biol. 2013 ; 45 (10). 2230-2238
63. Langen RC, Gosker HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013 ; 45 (10). 2245-2256
64. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle. 2012 ; 3 (4). 225-237
65. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002 ; 85 (1). 173-183
66. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest. 1996 ; 97 (6). 1447-1453
67. Lemire BB, Debigare R, Dube A, Theriault ME, Cote CH, Maltais F. MAPK signaling in the quadriceps of patients with chronic obstructive pulmonary disease. J Appl Physiol. 2012 ; 113 (1). 159-166
68. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007 ; 71 (2). 146-152
69. Debigare R, Cote CH, Maltais F. Ubiquitination and proteolysis in limb and respiratory muscles of patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2010 ; 7 (1). 84-90
70. Vogiatzis I, Simoes DC, Stratakos G, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J. 2010 ; 36 (2). 301-310
71. Gielen S, Adams V, Mobius-Winkler S, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003 ; 42 (5). 861-868
72. Ju C-R, Chen R-C. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med. 2012 ; 106 (1). 102-108
73. Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012 ; 16 (1). 95-131
74. von Haehling S, Steinbeck L, Doehner W, Springer J, Anker SD. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol. 2013 ; 45 (10). 2257-2265
75. Provinciali M, Cardelli M, Marchegiani F. Inflammation, chronic obstructive pulmonary disease and aging. Curr Opin Pulm Med. 2011 ; 17: S3 - S10
76. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation. 2012 ; 125 (22). 2716-2727
77. Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 ; 166 (4). 485-489
78. Boivin MA, Battah SI, Dominic EA, et al. Activation of caspase-3 in the skeletal muscle during haemodialysis. Eur J Clin Invest. 2010 ; 40 (10). 903-910
79. Zamboni M, Rossi A, Corzato F, Bambace C, Mazzali G, Fantin F. Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr Metab Immune Disord Drug Targets. 2013 ; 13 (1). 58-67
80. Fahal IH. Uraemic sarcopenia: aetiology and implications [published online April 25, 2013]. Nephrol Dial Transplant. :
81. Pupim LB, Heimburger O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int. 2005 ; 68 (5). 2368-2374
82. Segura-Orti E, Johansen KL. Exercise in end-stage renal disease. Semin Dial. 2010 ; 23 (4). 422-430
83. Cheema B, Abas H, Smith B, et al. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol. 2007 ; 18 (5). 1594-1601
84. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol. 2006 ; 17 (8). 2307-2314
85. Storer TW, Casaburi R, Sawelson S, Kopple JD. Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transplant. 2005 ; 20 (7). 1429-1437
86. Headley S, Germain M, Mailloux P, et al. Resistance training improves strength and functional measures in patients with end-stage renal disease. Am J Kidney Dis. 2002 ; 40 (2). 355-364
87. Man WD, Kemp P, Moxham J, Polkey MI. Exercise and muscle dysfunction in COPD: implications for pulmonary rehabilitation. Clin Sci (Lond). 2009 ; 117 (8). 281-291
88. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 ; 181 (10). 1072-1077
89. Balakrishnan VS, Rao M, Menon V, et al. Resistance training increases muscle mitochondrial biogenesis in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010 ; 5 (6). 996-1002
90. Lewis MI, Fournier M, Storer TW, et al. Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol. 2007 ; 103 (4). 1299-1310
91. Garcia-Pagan JC, Santos C, Barbera JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology. 1996 ; 111 (5). 1300-1306
92. Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006 ; 2 (3). 146-159
93. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004 ; 64 (7). 725-750
94. Dodson S, Hancock ML, Johnston MA, Steiner MS. GTx-024, a selective androgen receptor modulator (SARM), improves physical function in non-small cell lung cancer (NSCLC) patients with muscle wasting. J Cachexia Sarcopenia Muscle. 2011 ; 2 (4). 259
95. Dodson S, Hancock ML, Johnston MA, Steiner MS. In a phase IIb trial GTx-024 overcomes the negative impact of >8% weight loss on overall survival in non-small cell lung cancer (NSCLC) subjects. J Cachexia Sarcopenia Muscle. 2011 ; 2 (4). 259
96. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 1997 ; 156 (6). 1800-1806
97. Pupim LB, Flakoll PJ, Yu C, Ikizler TA. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr. 2005 ; 82 (6). 1235-1243
98. Garibotto G, Barreca A, Russo R, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest. 1997 ; 99 (1). 97-105
99. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol. 2005 ; 16 (7). 2111-2118
100. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005 ; 128 (3). 1187-1193
101. Miki K, Maekura R, Nagaya N, et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One. 2012 ; 7 (5). e35708
102. Fitschen PJ, Wilson GJ, Wilson JM, Wilund KR. Efficacy of beta-hydroxy-beta-methylbutyrate supplementation in elderly and clinical populations. Nutrition. 2013 ; 29 (1). 29-36
103. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002 ; 183 (4). 471-479
104. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000 ; 24 (3). 133-139
105. Marcora S, Lemmey A, Maddison P. Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr. 2005 ; 24 (3). 442-454
106. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002 ; 359 (9310). 926-930
107. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005 ; (2). CD004310
108. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr. 2000 ; 10 (1). 36-43
109. Dasarathy S, McCullough AJ, Muc S, et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol. 2011 ; 54 (5). 915-921
110. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 ; 12: CD000998
111. Dal Negro RW, Aquilani R, Bertacco S, Boschi F, Micheletto C, Tognella S. Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia. Monaldi Arch Chest Dis. 2010 ; 73 (1). 25-33
112. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr. 1997 ; 16 (2). 43-55
113. Rozentryt P, von Haehling S, Lainscak M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010 ; 1 (1). 35-42
114. Heidland A, Fazeli G, Klassen A, et al. Neuromuscular electrostimulation techniques: historical aspects and current possibilities in treatment of pain and muscle wasting. Clin Nephrol. 2013 ; 79: S12 - S23
115. Vivodtzev I, Debigare R, Gagnon P, et al. Functional and muscular effects of neuromuscular electrical stimulation in patients with severe COPD: a randomized clinical trial. Chest. 2012 ; 141 (3). 716-725